The notion that a proportion of ATCs exhibit MMR deficiency should therefore not be overlooked, as MMR deficient tumors could mandate specific therapeutic considerations, and as the hypermutability in turn might give rise to additional targetable mutations[44]. This evidence concerns the gene MRC1 and hyperinsulinemic hypoglycemia, familial, 4.